This company develops gene detection kits for diagnosing and monitoring leukemia and infectious diseases. Their kits enable simultaneous, cost-effective detection of fusion genes, helping healthcare providers effectively diagnose and stratify patients.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting gene fusions in leukemia and identifying high-risk HPV strains are often time-consuming, complex, and costly, hindering rapid diagnosis and personalized treatment decisions. Existing methodologies may involve multiple steps, such as karyotyping, FISH, and RT-PCR, increasing lab workload and turnaround time.
Solution
QuanDx develops and commercializes molecular diagnostic kits based on its patented Yin-Yang Probe technology and melting curve analysis for rapid and cost-effective detection of fusion genes in leukemia and genotyping of high-risk HPV strains. The Q-Fusion leukemia screening kits enable simultaneous detection of multiple fusion genes, aiding in accurate diagnosis, prognosis, treatment stratification, and disease monitoring. The MeltPro High-Risk HPV Genotyping Assay allows for automatic result interpretation in a single tube reaction, with a dry format that simplifies shipping and storage. These assays are compatible with commonly used real-time PCR instruments and provide results within hours, reducing the complexity and expense associated with traditional methods.
Target Audience
The primary target audience includes clinical and research laboratories, hospitals, and biotech/pharmaceutical companies requiring rapid, cost-effective, and multiplexed molecular diagnostic tools for leukemia and infectious disease management.
Features
- **Yin-Yang Probe Technology:** Proprietary technology for nucleic acid detection, offering superior flexibility, specificity, and multiplexing capabilities.
- **Q-Fusion Leukemia Screening Kits:** Multiplex assays for simultaneous detection of up to 30 fusion genes and 140+ breakpoints relevant to CML, AML, and ALL.
- **MeltPro High-Risk HPV Genotyping Assay:** Utilizes 4-color melting curve analysis (MMCA) to identify 14 high-risk HPV genotypes in a single reaction.
- **Rapid Turnaround:** Leukemia fusion gene detection in 2-3 hours.
- **Compatibility:** Kits are compatible with most current real-time qPCR instruments, including Bio-Rad CFX96, ABI7500, and Stratagene Mx3000P/Mx3005P.
- **Internal Controls:** Leukemia kits include GUSB housekeeping genes, positive controls, and negative controls to ensure assay accuracy.
- **Dry Format:** HPV assay uses a dry format for easy shipping and storage.